Abiomed Reaffirmed at Neutral – Analyst Blog
We retain our Neutral recommendation on Abiomed Inc (ABMD) following the company’s record first-quarter fiscal 2013 results which edged past the Zacks Consensus Estimates. Adjusted earnings per share came in at 8 cents,...
Read More